Candel Therapeutics Inc (CADL)

$5.92 +0.05 (0.85%)
Market Cap 320.60M
Revenue (ttm) 0.00
Net Income (ttm) -55.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.06
Volume 461,500
Avg Vol 815,032
Day's Range N/A - N/A
Shares Out 54.90M
Stochastic %K 26%
Beta -0.93
Analysts Strong Sell
Price Target $18.62

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 916 5445
Address:
117 Kendrick Street, Suite 450, Needham, United States
Xanderzzzzzzz
Xanderzzzzzzz Feb. 4 at 3:31 AM
$CADL Updated clinical data on NSCLC and Prostate in Q1 !!!!!!! Could be any day !!!!
0 · Reply
hegdaom
hegdaom Feb. 4 at 3:31 AM
$CAPR $CADL
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 4 at 3:29 AM
$CADL BLA readiness halfway through !!
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 4 at 3:10 AM
$CADL https://www.today.com/popculture/rob-gronkowski-bruce-arians-super-bowl-ad-prostate-cancer-screening-rcna256458
0 · Reply
Clemente4141
Clemente4141 Feb. 4 at 12:53 AM
$CADL Reverse head and shoulders pattern here. Will the break occur in the next 5 trading days? Hang on and find out
2 · Reply
The1Albatross
The1Albatross Feb. 3 at 10:31 PM
$CADL Added today
2 · Reply
LongLTC
LongLTC Feb. 3 at 10:11 PM
$CADL Bargain shopping today :)
3 · Reply
Kittyc803
Kittyc803 Feb. 3 at 9:55 PM
$CADL Bean 🫘 by bean 🫘 the bag 💼 gets fillied 👍
0 · Reply
MRCPLS
MRCPLS Feb. 3 at 9:45 PM
$CADL Last year nsclc data cut off was march 3 and drop was march 26... I'd guess they will let it simmer for exactly 12 month unless they intend to drop at a conference? But I guess tak is confindent in data, otherwise they wouldn't have mentioned long tail in recent post. I think BP is more interested in partnering nsclc due to larger tam and easier recruitment. Partnership and data drop might coincide?
0 · Reply
Kingjake26
Kingjake26 Feb. 3 at 9:02 PM
$CAPR $CADL Hope people are adding on dips if they can.
1 · Reply
Latest News on CADL
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 2, 2026, 4:05 PM EST - 1 day ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 17, 2025, 4:05 PM EST - 2 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 13, 2025, 8:25 AM EST - 2 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 4, 2025, 9:00 AM EST - 3 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Nov 3, 2025, 8:05 AM EST - 3 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 16, 2025, 8:05 AM EDT - 3 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 4 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

Oct 14, 2025, 8:10 AM EDT - 4 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 14, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now

Oct 13, 2025, 10:22 AM EDT - 4 months ago

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 4 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 29, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 4 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Sep 7, 2025, 10:53 AM EDT - 5 months ago

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Sep 5, 2025, 12:47 PM EDT - 5 months ago

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Sep 2, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 28, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 14, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 24, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jul 9, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 24, 2025, 9:05 AM EDT - 8 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 23, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 6, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 28, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 27, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 22, 2025, 5:05 PM EDT - 9 months ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 13, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Candel Therapeutics to Present at Upcoming Investor Conferences

May 6, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Apr 1, 2025, 8:01 AM EDT - 11 months ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 26, 2025, 4:05 PM EDT - 11 months ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 20, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 18, 2025, 8:00 AM EDT - 11 months ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 13, 2025, 4:15 PM EDT - 11 months ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Feb 25, 2025, 4:52 PM EST - 1 year ago

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Feb 25, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics: Entering Its Pivotal Year

Feb 20, 2025, 10:45 AM EST - 1 year ago

Candel Therapeutics: Entering Its Pivotal Year

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Best-Performing Stocks Of 2024

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Dec 13, 2024, 8:53 AM EST - 1 year ago

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

EGHT

Candel Therapeutics Announces Pricing of Public Offering

Dec 12, 2024, 11:00 PM EST - 1 year ago

Candel Therapeutics Announces Pricing of Public Offering

Candel Therapeutics Announces $80 Million Proposed Public Offering

Dec 12, 2024, 4:51 PM EST - 1 year ago

Candel Therapeutics Announces $80 Million Proposed Public Offering

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Dec 11, 2024, 12:19 PM EST - 1 year ago

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Candel Therapeutics Stock Surges Over 100% - Here's Why

Dec 11, 2024, 9:19 AM EST - 1 year ago

Candel Therapeutics Stock Surges Over 100% - Here's Why

Candel Therapeutics' cancer drug meets late-stage trial goals

Dec 11, 2024, 7:09 AM EST - 1 year ago

Candel Therapeutics' cancer drug meets late-stage trial goals

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Dec 11, 2024, 7:00 AM EST - 1 year ago

Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Nov 5, 2024, 9:00 AM EST - 1 year ago

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think

Nov 1, 2024, 12:40 PM EDT - 1 year ago

Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think

Xanderzzzzzzz
Xanderzzzzzzz Feb. 4 at 3:31 AM
$CADL Updated clinical data on NSCLC and Prostate in Q1 !!!!!!! Could be any day !!!!
0 · Reply
hegdaom
hegdaom Feb. 4 at 3:31 AM
$CAPR $CADL
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 4 at 3:29 AM
$CADL BLA readiness halfway through !!
0 · Reply
Xanderzzzzzzz
Xanderzzzzzzz Feb. 4 at 3:10 AM
$CADL https://www.today.com/popculture/rob-gronkowski-bruce-arians-super-bowl-ad-prostate-cancer-screening-rcna256458
0 · Reply
Clemente4141
Clemente4141 Feb. 4 at 12:53 AM
$CADL Reverse head and shoulders pattern here. Will the break occur in the next 5 trading days? Hang on and find out
2 · Reply
The1Albatross
The1Albatross Feb. 3 at 10:31 PM
$CADL Added today
2 · Reply
LongLTC
LongLTC Feb. 3 at 10:11 PM
$CADL Bargain shopping today :)
3 · Reply
Kittyc803
Kittyc803 Feb. 3 at 9:55 PM
$CADL Bean 🫘 by bean 🫘 the bag 💼 gets fillied 👍
0 · Reply
MRCPLS
MRCPLS Feb. 3 at 9:45 PM
$CADL Last year nsclc data cut off was march 3 and drop was march 26... I'd guess they will let it simmer for exactly 12 month unless they intend to drop at a conference? But I guess tak is confindent in data, otherwise they wouldn't have mentioned long tail in recent post. I think BP is more interested in partnering nsclc due to larger tam and easier recruitment. Partnership and data drop might coincide?
0 · Reply
Kingjake26
Kingjake26 Feb. 3 at 9:02 PM
$CAPR $CADL Hope people are adding on dips if they can.
1 · Reply
oldmanrizzer
oldmanrizzer Feb. 3 at 8:59 PM
$CADL This shit is so freaking rangebound . Why am I even here tbh? I could cash out and come back here in a year and it will be at the same freaking range.
1 · Reply
stu4
stu4 Feb. 3 at 8:30 PM
$CADL @drizz is a cousin of @Tiffiny from $SAVA She mouthed off over there and went broke !!! Saying she was always buying ….in the 100’s ..60’s …$40’ and BOOM BUSTED At $2
1 · Reply
stu4
stu4 Feb. 3 at 8:27 PM
$CADL ….rumor has it @drizz , has more shares than BLK , Fidelity, Baker Bros , Macquarie, VOYA, Wellington mgmt all combined. !!! There are no shares , yet, hahahaha , there is no squeeze Accumulating every dip , is the Biggest LIE since TRUMP said “ I don’t know the woman “ I’ll end the war in Ukraine, day one of my presidency, or before I take office “ Keep up your lies @drizz , you could be President of NOTHING !! Drizz has 8M shares the rest are owned by Tak and the Board ……put your hip boots on, drizz is getting very anxious and the bs is now waist high
1 · Reply
Kingjake26
Kingjake26 Feb. 3 at 8:17 PM
$CADL Greta day today. $CAPR My two favorites
0 · Reply
CO145
CO145 Feb. 3 at 7:48 PM
$CADL super conservative 65000 patients x 10% penetration X $140,000 = $910M sales x 4x = $3.6B mkt cap 40% penetration over time = $3.6B sales x 4x = $14.5B mkt cap What will BP pay? certainly above $3.6B
1 · Reply
Stocksprofessional
Stocksprofessional Feb. 3 at 7:44 PM
$CADL Big institutions — along with retail investors — are rotating out of the overhyped AI, quantum computing, and high-beta tech space, and shifting capital into pharmaceuticals and oncology, sectors that are largely insulated from economic cycles and macro noise.
0 · Reply
ragman1
ragman1 Feb. 3 at 7:18 PM
$CADL added 1k at shares $5.70.
0 · Reply
Timmyyy
Timmyyy Feb. 3 at 7:17 PM
$CADL double bottom on the weekly?
0 · Reply
oldmanrizzer
oldmanrizzer Feb. 3 at 7:11 PM
$CADL About to give up..
0 · Reply
moneymaker444
moneymaker444 Feb. 3 at 6:43 PM
$CADL I'll grab a little more ! TY
1 · Reply
Stocksprofessional
Stocksprofessional Feb. 3 at 5:51 PM
$CADL adding more
0 · Reply
Deeconomics
Deeconomics Feb. 3 at 5:45 PM
$CADL Dr. PPT and Vertex Pharmaceuticals CEO Reshma Kewalramani both prioritize robust BLA submissions over rushed submissions, both are headquartered in Massachusetts and both are seeking partnerships. 🤔 A partnership like that would have a phenomenal impact on patients health. AI Overview: It is highly plausible for Candel Therapeutics and cash rich Vertex Pharmaceuticals to collaborate, fostering a high likelihood of complementary non-overlapping areas of expertise and easier logistical coordination for partnership discussions. Vertex actively seeks external partnerships in new disease areas to diversify its pipeline, while Candel is actively seeking partners for commercialization. While Candel is in oncology and Vertex has historically been in genetic disease, Vertex has explicitly stated its interest in expanding its portfolio into new areas. Candel's focus on high-unmet-need cancer types like recurrent high-grade glioma matches Vertex’s "high unmet need" criteria.
0 · Reply